130508-04-2

Upstream product

• 37784-17-1 N-(tert-butoxycarbonyl)-D-proline 
• 70-11-1 α-bromoacetophenone 
• 24424-99-5 di-tert-butyl dicarbonate 
• 98-86-2 acetophenone 
• 344-25-2 D-Prolin 

Downstream Products

• 1616705-87-3 (R)-tert-butyl 2-(5-phenyl-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1311255-08-9 (R)-5-phenyl-2-(pyrrolidin-2-yl)-1H-imidazole 
• 1616705-89-5 (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a-((R)-2-(5-phenyl-1H-imidazol-2-yl)pyrrolidine-1-carbonyl)-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-yl acetate 
• 1616705-90-8 ((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-3a-yl)((R)-2-(5-phenyl-1H-imidazol-2-yl)pyrrolidin-1-yl)methanone 
• 1616705-12-4 2,2-dimethyl-4-oxo-4-((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a((R)-2-(5-phenyl-1H-imidazol-2-yl)pyrrolidine-1-carbonyl)-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-yloxy)butanoic acid 
• 1616705-13-5 3,3-dimethyl-5-oxo-5-((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a-((R)-2-(5-phenyl-1H-imidazol-2-yl)pyrrolidine-1-carbonyl)-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-yloxy)pentanoic acid 

Relevant academic research and scientific papers

NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS

The invention relates to novel betulinic acid derivatives and related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases. These compounds are esterified in position 3 and are substituted in position 17 of the betulinic acid structure, via a linking group W, by a saturated 5-7 membered nitrogen-heterocycle.

Novel peptidyl carbamate inhibitors of the enzyme elastase

Compounds selected from the group consisting of a compound of the formula STR1 and compound of the formula STR2 wherein x is 1 or 2, Y is carbobenzoxy or benzoyl, and XR is STR3 have use as elastase enzyme inhibitors. Particularly potent are the L-proline diastereomers. Elastase Enzyme inhibitory compositions comprise a carrier and an elastase enzyme inhibiting amount of the compounds of the invention. A method of selectively inhibiting the enzyme elastase in an animal or a human in need of such treatment comprises administering to the animal or human an enzyme elastase inhibiting amount of one of the compounds of the invention or a composition thereof.